Translation of "Tiefe venenthrombosen" in English

In addition, special precaution should be taken in patients with predisposition for development of deep vein thrombosis (DVTs).

VTE reporting rate is increasing.

There is also a slim possibility of blood clots and deep vein thrombosis.

In the EU there are approximately 550,000 deaths due to VTE each year.

Graduated compression reduces risk of deep vein thrombosis or blood clots.

It is estimated that more than 680,000 DVT events occur in the EU each year.

It is estimated that nearly 700,000 DVT events occur in the EU each year.

Complications related to knee surgery in general may include deep vein thrombosis (blood clotting in a deep vein) and pulmonary embolism (blood clotting in the lung due to blockage of a lung artery).

Concomitant administration of erythropoietic agents or previous history of DVT may also increase thrombotic risk in these patients.

HRT is associated with a 1.3-3 fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism.

The majority (70/80) of the recorded VTE events were venographically detected non-symptomatic cases of DVT.

HRT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism.

In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone.

Across all placebo-controlled clinical trials of ospemifene, deep vein thrombosis occurred at a frequency of approximately 3.65 cases per 1,000 patient years on 60 mg ospemifene (95% confidence interval of 0.44 to 13.19) versus 3.66 cases per 1,000 patient years for placebo (95% confidence interval of 0.09 to 20.41; relative risk is 1.0).

The combination of lenalidomide, thalidomide or pomalidomide with dexamethasone is associated with an increased risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma (see section 4.5).

Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients receiving baricitinib.

Following coronary artery bypass graft surgery, patients administered Dynastat have a higher risk of adverse reactions such as: cardiovascular/thromboembolic events (including myocardial infarction, stroke/TIA, pulmonary embolus, and deep vein thrombosis; see sections 4.3 and 5.1), deep surgical infections, and sternal wound healing complications.

There was a significantly (p < 0.05) greater incidence of cardiovascular/thromboembolic events (myocardial infarction, ischemia, cerebrovascular accident, deep vein thrombosis and pulmonary embolism) detected in the parecoxib/valdecoxib treatment group compared to the placebo/placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).

Cardiovascular/ thromboembolic events include myocardial infarction, stroke/ TIA, pulmonary embolus and deep vein thrombosis (see section 4.3 and 5.1).

Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins.

Patients receiving pomalidomide either in combination with bortezomib and dexamethasone or in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident).

Patients receiving pomalidomide in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident).